Overview
Cell, tissue and gene therapy products (CTGTPs) are novel and complex therapeutics which seek to address unmet medical needs in life-threatening and rare conditions. Their development requires integrated scientific, regulatory, and quality systems that manage biological variability, supply‑chain controls and lifecycle risks from discovery through commercialisation.
In 2020, the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was set up to centralise resources, manpower and capabilities across Singapore to enable more robust operations and scale up manufacturing of cell therapy products to increase patient access to these treatments. With its facility launched in 2023, ACTRIS has supported the development and manufacture of these treatments to serve local healthcare needs, including the development of the Chimeric Antigen Receptor T-cell (CAR-T) therapy, where a patient’s own immune cells, are engineered to target specific cancer cells.
Bringing together Singapore’s CTGTP experts to provide practical guidance for safe and compliant development of CTGTPs, the webinar features Dr Ong Lee Lee, who will share the regulatory frameworks for CTGTPs in Singapore and Mr Vincent Jong, who will outline the end‑to‑end project pathway across different development phases of CTGTPs.
Schedule
Date: 25 Jun 2026, Thursday
Time: 2:00 PM - 3:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: Online
